Marc Besselink The Lancet Gastroenterology & Hepatology DPCG Pancreas Verona Important work! Will read it in detail and discuss it in team Karolinska-HPB asap.

Very important data 📊 underscoring the need for biomarkers in #pancreaticcancer PANCAID
Karolinska-HPB Ernesto Sparrelid Poya Ghorbani

Ville Sallinen ALPS Meeting Ernesto Sparrelid Karolinska-HPB Completely agree…Need for european regulations in fellowship??🧐

Educational session at #ALPS 2024 🇮🇹 starts with excellent lecture: Prof Steve Wigmore @HPBjournal, our E-AHPBA IHPBA journal on “How to Write a Good Paper”.
🔑 Check out BJS Academy
🔑 Do a a good study
🔑 Write like you speak
🔑 Use short sentences
🔑 Follow the journal…

Well, „observing“ out Karolinska-HPB Ernesto Sparrelid Stefan Gilg fellows, I can safely state that they indeed DO surgery as 1️⃣ surgeons, inclusive MIS.
BUT⚠️ this is not all! They are also immersed intensively in our academic environment! Magnus Nilsson Karolinska Institutet

ALPS meeting ALPS Meeting - Ernesto Sparrelid from Karolinska-HPB giving an excellent overview on the landscape of HPB fellowships in Europe. Much still to do.

If you think of applying, ask the program director this question: How many procedures will I be doing as the first surgeon?

Postoperative Hyperamilasemia (POH) 🧪 is an early predictor od POPF after distal pancreatectomy

🇮🇹🇸🇪🇳🇴 1.2 k DP - POH 18% / POPF 29%

🐳 POPF doubled once POH diagnosed (46%)

🧑‍🔬 POH early predicts POPF severity and additional morbidity / mortality

👉journals.lww.com/annalsofsurger…

A great and exciting week is coming to an end. Eight HPB-Cases I attended this week, including my first performed robotic distal pancreatectomy and first independent Whipple. What a fantastic fellowship! Thank you for the support and trust: Karolinska-HPB Ernesto Sparrelid Stefan Gilg

Tim Reese Hannes Jansson jengstrand Poya Ghorbani PatrikLarsson Kjetil Søreide Johanna Samola Winnberg Way to go Tim. It shows the value of Karolinska-HPB training! Spread the word! Stefan Gilg Ernesto Sparrelid

Congratulations to the #NORPACT team 🇳🇴🇸🇪🇩🇰🇫🇮 led by Knut Jørgen Labori for delivering us with much needed evidence on #neoadjuvant tx in resectable #PancreaticCancer The Lancet Gastroenterology & Hepatology

Almost by definition, any RCT-design can, will, and should be criticised but only through RCTs will we…

Giovanni Marchegiani The Lancet Gastroenterology & Hepatology Ville Sallinen Knut Jørgen Labori Marc Besselink Kjetil Søreide Ernesto Sparrelid Karolinska-HPB Julio Mayol Julie Hallet Lee M. Ocuin MD, FACS Let's Win Pancreatic Cancer 💜 This ‘real world’ multi centre RCT is excellent work by all involved. It also sheds light on ‘agenda based surgery’ when the result doesn’t meet some expectations. This study has faced rigorous review across the 🌎 with some very forthright views 1/

Giovanni Marchegiani The Lancet Gastroenterology & Hepatology Ville Sallinen Knut Jørgen Labori Marc Besselink Kjetil Søreide Ernesto Sparrelid Karolinska-HPB Julio Mayol Julie Hallet Lee M. Ocuin MD, FACS Let's Win Pancreatic Cancer 💜 Yet some retrospective case series with nowhere near the same scientific validity are lauded 🤔🤷‍♂️. What is clear is that we have a long way to go, and a blunder bus ‘1 size fits all’ will not significantly improve outcomes

NORPACT-1 published in The Lancet Gastroenterology & Hepatology. Phase-2 RCT. Neoadjuvant FOLFIRINOX vs upfront surgery in resectable pancreatic head cancer. Great team effort in 12 centers in the Nordic countries
🇳🇴🇸🇪🇩🇰🇫🇮

✅Neoadjuvant FOLFIRINOX did not improve survival compared to upfront surgery

NORPACT-1 trial from 🇳🇴🇸🇪🇫🇮🇩🇰 out The Lancet Gastroenterology & Hepatology!

Neoadjuvant FOLFIRINOX versus upfront surgery in resectable #pancreaticcancer , 140 pts

Median survival: neoadjuvant 25mo, surgery 39mo (HR 1.52 [1.00-2.33])

❌ No benefit from neoadjuvant!

Free link: sciencedirect.com/science/articl…

Neoadjuvant FOLFIRINOX 🤜🤛upfront surgery for resectable pancreatic cancer

NORPACT-1 out 🔥 now The Lancet Gastroenterology & Hepatology

📈 Median OS 25 vs. 38 months and resection rate did not differ

💉 60% neoadjuvant group had severe adverse event 🚨

🫵Comments?🧐

👉 sciencedirect.com/science/articl…

BJS BJS Academy SoMe4HPB SoMe4Surgery Ernesto Sparrelid Karolinska-HPB Stefan Gilg jengstrand +++

Great oportunity for an HPB fellow , check this out 👇🏻
SoMe4HPB E-AHPBA European Society of Surgical Oncology (ESSO) IHPBA SoMe4Surgery #HPB #fellowship